EvaluatePharma Ltd

EvaluatePharma 2018 Outlook: Novartis #1 and Pfizer Sole USA Co in Top 5

London (ots/PRNewswire) - EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Novartis is expected to take the top spot amongst the world's pharmaceuticals manufacturers, in terms of prescription (Rx) drug sales, starting in 2014 and remains at the top through 2018. Only one US-based drug maker, Pfizer, will rank among the top five, with Sanofi, GlaxoSmithKline and Roche also topping the table. Further down the league table sizeable shifts both up and down the rankings are forecast, as pipeline successes and failures drive the future fortunes of the world's biggest pharma companies (see table).

For more in-depth analysis and commentary on this news please visit EP Vantage: http://ow.ly/awKnz.

                            World's Top 15 Pharma Companies
                            Market Rank        Rx Pharma Sales ($bn)
                                                                          Annual
                                                                          growth
                        2011 2014 2016 2018     2011  2014  2016  2018   2011-18
        Novartis           2    1    1    1     46.7  47.6  49.0  50.8      1.2%
        Sanofi             4    3    3    2     39.3  42.9  45.6  47.8      2.9%
        Pfizer             1    2    2    3     53.5  46.9  46.5  47.1     -1.8%
        GlaxoSmithKline    6    6    4    4     35.0  38.5  43.1  45.6      3.9%
        Roche              5    5    5    5     37.0  40.7  42.7  45.0      2.8%
        Merck & Co         3    4    6    6     41.9  40.9  42.6  41.0     -0.3%
        Johnson &
        Johnson            9    8    7    7     22.3  25.8  27.2  27.3      2.9%
        Teva              11   10   10    8     17.1  22.1  22.8  23.3      4.5%
        AstraZeneca        7    7    8    9     32.4  26.7  25.2  22.1     -5.3%
        Abbott
        Laboratories       8    9    9   10     22.4  23.7  23.9  22.1     -0.2%
        Bristol-Myers
        Squibb            12   15   11   11     16.9  14.9  18.9  21.4      3.4%
        Novo Nordisk      17   14   13   12     12.4  15.6  18.0  19.9      7.0%
        Takeda            14   12   12   13     15.2  16.8  18.7  19.5      3.6%
        Bayer             16   16   16   14     13.6  14.6  15.7  16.5      2.7%
        Gilead Sciences   21   20   17   15      8.1  10.8  15.0  15.7      9.9% 

About EvaluatePharma Ltd.

The market intelligence and analysis company EvaluatePharma Ltd was the first to supply reliable consensus forecasts of global drug sales and has just updated the standardized worldwide financial and forecast models with consensus product sales forecasts to 2018. EvaluatePharma also provides data on R&D pipelines, clinical trials, licensing deals, patent risk, M&A activity, valuation through product Net Present Value analysis plus daily commentary and analysis from the EP Vantage(R) news service.

EvaluatePharma Ltd, headquartered in London, England and in North America is represented by EvaluatePharma USA, Inc.

http://www.evaluatepharma.com

Media Contacts: Andrew Beaven Marketing Director, EvaluatePharma Ltd Tel: +44(0)20-7377-0800 Email: andrewb@evaluatepharma.com EvaluatePharma Ltd 11-29 Fashion Street London E1 6PX United Kingdom Christine Lindgren Tel: +1-617-573-9458 Email: christinel@evaluatepharma.com EvaluatePharma USA 15 Broad St. Boston, MA 02109 United States

 


Das könnte Sie auch interessieren: